

**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement of Financial status**  
**as of 31 of December 2019**

	31.12.2019	31.12.2018
	BGN'000	BGN'000
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	26 985	25 754
Intangible assets	2 720	2 871
Investment in minority interest	1	1
Trade receivables	4 968	4 968
<b>Total non-current assets</b>	<b>34 674</b>	<b>33 594</b>
<b>Current assets</b>		
Inventories	7 959	5 491
Trade and other receivables	73 985	71 608
Current corporate income tax	-	92
Treasury shares redeemed	1	4
Cash and cash equivalents	42	250
<b>Total current assets</b>	<b>81 987</b>	<b>77 445</b>
<b>Total assets</b>	<b>116 661</b>	<b>111 039</b>
<b>LIABILITIES</b>		
<b>Equity</b>		
Share capital	82 200	72 200
Reserves	11 800	10 601
Retained earnings	2 845	11 199
<b>Total</b>	<b>96 845</b>	<b>94 000</b>
<b>Non-current liabilities</b>		
Long-term loans	1 861	180
Deferred tax liabilities	1 264	1 264
Retirement benefit obligations	119	119
<b>Total non-current liabilities</b>	<b>3 244</b>	<b>1 563</b>
<b>Current liabilities</b>		
Trade and other liabilities	6 228	4 186
Short-term loans	9 787	9 785
Current portion of long-term loans	367	409
Current corporate income tax		217
Other tax liabilities	190	879
<b>Total current liabilities</b>	<b>16 572</b>	<b>15 476</b>
<b>Total liabilities</b>	<b>19 816</b>	<b>17 039</b>
<b>Total equity and liabilities</b>	<b>116 661</b>	<b>111 039</b>

Date of preparation: 28.01.2020

Sofia

Prepared by:.....

/ P. Moneva /

Executive Director:.....

/B. Georgiev/

**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement of comprehensive income**  
**as of 31 of December 2019**

	<b>31.12.2019</b>	<b>31.12.2018</b>
	<b>BGN'000</b>	<b>BGN'000</b>
Revenue	34 788	38 013
Other income	281	46
<b>Total income</b>	<b>35 069</b>	<b>38 059</b>
Carrying amount of goods sold	(748)	(2 326)
Changes in inventories of finished products and work in progress	1 799	(118)
Materials and services	(24 289)	(13 605)
Personnel expenses	(4 341)	(3 891)
Depreciation / amortisation expenses	(3 315)	(3 273)
Other expenses	(797)	(2 419)
Finance income	36	468
Finance costs	(355)	(476)
<b>Total expenses</b>	<b>(32 010)</b>	<b>(25 640)</b>
<b>Profit before taxation</b>	<b>3 059</b>	<b>12 419</b>
Corporate income tax expense	(214)	(1 220)
<b>Profit/Loss for the period</b>	<b>2 845</b>	<b>11 199</b>
<b>Total comprehensive income for the period</b>		
Earnings per share / in BGN per 1 share /	0.04	0.20

Date of preparation: 28.01.2020


Sofia

Prepared by:.....

/ P. Moneya /

Executive Director:.....

/B. Georgiev/



**Tchaikapharma High Quality Medicines Inc.**  
**Interim cash flow statement**  
**as of 31 of December 2019**

	<b>31.12.2019</b>	<b>31.12.2018</b>
	<i>BGN'000</i>	<i>BGN'000</i>
<b>Cash flows from operating activities</b>		
Proceeds from sale of finished products, goods and services	30 470	28 229
Payments to suppliers of materials, goods and services	(17 623)	(13 818)
Payments to personnel	(3 885)	(3 788)
Payments of interest and dividends	(339)	1 291)
Other proceeds / payments	(6 570)	(6 990)
<b>Net cash flows</b>	<b>2 053</b>	<b>2 342</b>
<b>Cash flows from investing activities</b>		
Payments on non-current assets acquired	(989)	(1 399)
<b>Net cash flows</b>	<b>(989)</b>	<b>(1 399)</b>
<b>Cash flows from financial activities</b>		
Proceeds from loans	217	188
Payments on loans	(215)	(188)
Payment of interest, dividends	(197)	(196)
Payments on finance lease	(1 073)	(527)
Other proceeds/payments from treasury shares	(4)	6
<b>Net cash flows</b>	<b>(1 272)</b>	<b>(717)</b>
<b>Change in cash and cash equivalents</b>		
Cash and cash equivalents at the beginning of the period	250	24
Cash and cash equivalents at the end of the period	42	250

Date of preparation: 28.01.2020

Sofia

Prepared by:.....

/ P. Moneva /

Executive

Director:.....

/B. Georgiev /

**Tchaikapharma High Quality Medicines Inc.**  
**Interim statement on changes in equity**  
**as of 31 of December 2019**

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
<b>Balance as of 01.01.2018</b>	<b>63 400</b>	<b>3 626</b>	<b>5 546</b>	<b>8 831</b>	<b>82 303</b>
Profit/loss for the period				11 199	11 199
Other comprehensive income		498			498
Including from tax effect of the revaluation of property, plant and equipment		(72)			(72)
<b>Total comprehensive income</b>		<b>498</b>		<b>11 199</b>	<b>11 697</b>
Issue of shares by the owners	7 900			(7 900)	
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves			931	(931)	
<b>Total amount of income and expenses recognised during the period</b>	<b>7 900</b>		<b>931</b>	<b>(8 831)</b>	
<b>Balance as of 31.12.2018</b>	<b>72 200</b>	<b>4 124</b>	<b>6 477</b>	<b>11 199</b>	<b>94 000</b>
<b>Balance as of 01.01.2019</b>	<b>72 200</b>	<b>4 124</b>	<b>6 477</b>	<b>11 199</b>	<b>94 000</b>
Profit/loss for the period				2 845	2 845
Other comprehensive income					
<b>Total comprehensive income</b>				<b>2 845</b>	<b>2 845</b>
Issue of shares by the owners	10 000			(10 000)	
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves		79	1 120	(1 199)	
<b>Total amount of income and expenses recognised during the period</b>	<b>10 000</b>	<b>79</b>	<b>1 120</b>	<b>(11 199)</b>	
<b>Balance as of 31.12.2019</b>	<b>82 200</b>	<b>4 203</b>	<b>7 597</b>	<b>2 845</b>	<b>96 845</b>

Date of preparation: 28.01.2020  
Sofia

Prepared by:.....  
/P. Moneva/

Executive Director:.....  
/B. Georgiev /